AZN vs NVS
AstraZeneca PLC and Novartis AG, both Healthcare
Novartis AG is the larger company at $296B against $288B. On trailing earnings NVS is the cheaper of the two at a P/E of 20.4 against 26.4, a gap that is only a bargain if the two are growing at similar rates. Over the past year NVS returned +14% against +2.2% for AZN.
| Figure | AZN | NVS |
|---|---|---|
| Last close | $160 | $138 |
| Market cap | $288B | $296B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 26.4 | 20.4 |
| 1-year return | +2.2% | +14% |
| 5-year return | +57% | +80% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AstraZeneca PLC
Revenue of $31B in H2 2025, net income $4.9B.
Novartis AG
Revenue of $27B in H2 2025, net income $6.3B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.